Yahoo Finance8d
OS Therapies to acquire listeria programs from Ayala Pharmaceuticals
OS Therapies (OSTX) announced it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based immuno-oncology programs and related intellectual property assets from ...
Wear OS 6: Eligible watches, One UI 7 Watch, Gemini, & more
Wear OS 6 will likely transform Android watches with Gemini tricks and new fitness coaching. Here's what we know (and hope to ...
Business Wire9d
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate ...
The assets being acquired include a Phase 2 lung cancer and Phase1 prostate cancer program, in addition to the gaining direct ownership of the underlying IP related to OS Therapies’ lead asset ...
ETF Daily News7d
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals: MarketBeat News
As per the terms of the agreement, OS Therapies will pay an aggregate purchase price of $8 million. This will include $0.5 million in cash and $7.5 million worth of OS Therapies’ common shares.
OS Therapies to acquire listeria programs from Ayala Pharmaceuticals
OS Therapies (OSTX) announced it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based immuno-oncology ...